<DOC>
	<DOCNO>NCT02555085</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability single ascend intravenous ( IV ) dose single subcutaneous ( SC ) dose BIIB063 healthy volunteer . The secondary objective study estimate PK parameter single ascend IV dose BIIB063 ; estimate PK parameter absolute bioavailability ( F ) single SC dose BIIB063 ; evaluate immunogenicity single ascending dos BIIB063 .</brief_summary>
	<brief_title>Single Ascending Doses BIIB063 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Key All male subject female subject childbearing potential must practice least 1 highly effective method contraception ( i.e. , contraceptive measure failure rate &lt; 1 % per year ; estrogencontaining contraceptive prohibit ) study willing able continue contraception 4 month dose study treatment . Male subject must also willing refrain sperm donation least 4 month last dose study treatment . Male subject must unprotected sexual intercourse female pregnant breastfeeding study . Must body mass index 18 30 kg/m2 , inclusive . Must good health determine Investigator , base medical history , physical examination , 12lead ECG . Key History positive test result screen human immunodeficiency virus , hepatitis C virus antibody , hepatitis B virus ( define positive hepatitis B surface antigen [ HBsAg ] hepatitis B core antibody [ HBcAb ] ) . History clinically significant cardiac , endocrine , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , major disease , determine Investigator . Personal family history cardiovascular disease age 50 year , inherit disorder coagulation ( e.g. , Factor V Leiden , protein C S deficiency ) , antiphospholipid Ab syndrome ( APS ) . History meningococcal vaccination meningococcal meningitis , history hypersensitivity single component meningococcal vaccine ( include MENVEO ) , CRM197 , diphtheria toxoid , meningococcalcontaining vaccine . History tuberculosis ( TB ) positive QuantiFERONÂ®TB Gold test Personal history thromboembolic event Treatment prescription overthecounter medication within 14 day prior randomization ( exclude vitamin , dietary supplement , herbal preparation , progestinonly birth control , paracetamol 4 g/day 5 consecutive day ) . Current enrollment plan enroll interventional clinical study investigational treatment approve therapy investigational use administer within 3 month Current enrollment plan enroll drug , biologic device clinical study , treatment investigational drug approve therapy investigational use within 3 month Blood donation ( 1 unit ) within 3 month prior randomization . NOTE : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>